Helix BioPharma (TSE:HBP) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Helix BioPharma Corp. has received a U.S. patent for its innovative L-DOS47 platform, which targets tumors with high CEACAM6 expression, potentially enhancing cancer treatment outcomes. This development strengthens Helix’s position in the oncology market, offering new hope for patients with hard-to-treat cancers.
For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.
